2 completed, 2 terminated, 2 withdrawn, 1 recruiting. 6 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 2, Withdrawn 2, Suspended 1, Terminated 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Refractory Breast Carcinoma: new trials by email Literature Review of Refractory Breast Carcinoma trials Research Report on Refractory Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer Organoid-guided personalized treatment, Gemcitabine, Capecitabine - Breast Cancer, Refractory Breast Carcinoma | Phase 3 | Recruiting | Sun Yat-sen University | 302 | 2024-01-15 | 2024-02-20 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Abexinostat Tosylate, Fulvestrant, Palbociclib - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Withdrawn | Pamela Munster | 2021-03-31 | 2021-05-18 | |
| Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer Cyclophosphamide, Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM, Pembrolizumab - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2020-12-21 | 2025-04-29 | |
| Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations Alpelisib, Nab-paclitaxel - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2020-07-10 | 2026-07-07 |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer Alpha-tocopheryloxyacetic Acid, Trastuzumab - Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma | Phase 1 | Suspended | Veana Therapeutics | 24 | 2020-04-08 | 2024-07-10 |
| Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer Alpelisib, Enzalutamide - Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 18 | 2019-06-07 | 2024-10-10 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients Everolimus, Laboratory Biomarker Analysis, Letrozole - Advanced Malignant Solid Neoplasm, Estrogen Receptor Positive | Phase 1 | Completed | M.D. Anderson Cancer Center | 37 | 2014-07-17 | 2020-12-19 |
Breast Neoplasms (8) · Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Endometrioid (1) · Fallopian Tube Neoplasms (1) · Hodgkin Disease (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Ovarian Neoplasms (1)
Breast Diseases (8) · Neoplasms (8) · Neoplasms by Site (8) · Skin Diseases (8) · Skin and Connective Tissue Diseases (8) · Neoplasms by Histologic Type (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Endometrial Neoplasms (1)
Ogivri (3) · PF-05280014 (3) · Trastuzumab (3) · trastuzumab biosimilar HLX02 (3) · Alpelisib (2) · Gemcitabine (2) · Ontruzant (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid (1) · Acetic Acid (1) · Albumin-Bound Paclitaxel (1) · Antibodies, Monoclonal (1) · CT-P10 (1) · Capecitabine (1)
M.D. Anderson Cancer Center (3) · Mayo Clinic (1) · Pamela Munster (1) · Sun Yat-sen University (1) · Thomas Jefferson University (1) · Veana Therapeutics (1)
United States (6) · China (1)
Filip Janku (1) · Grzegorz S. Nowakowski, M.D. (1) · Meghan Karuturi (1) · Pamela N Munster, MD (1) · Senthilkumar Damodaran (1) · William Gwin, MD (1) · Yanxia Shi (1)
P30CA016672 (1)